What's Happening?
Kayla Barnes-Lentz, a 35-year-old host of the 'Longevity Optimization Podcast,' is actively pursuing experimental health protocols to delay menopause until the age of 60. Currently, the average age for
menopause in the U.S. is 52. Barnes-Lentz is focusing on improving her ovarian health to extend her fertile years, as she and her husband plan to have a large family. Her health regimen includes a strict lifestyle protocol, such as maintaining a regular sleep schedule, reducing stress, and following a Mediterranean diet. She also uses the MenoTime test by Timeless Biotech to assess her ovarian age, which currently stands at 30, five years younger than her chronological age. To further delay menopause, she is experimenting with treatments like rapamycin, red light therapy, and hyperbaric oxygen therapy, which are believed to address ovarian aging factors like egg loss and mitochondrial dysfunction.
Why It's Important?
The pursuit of delaying menopause has significant implications for women's health and longevity. Extending the fertile years could provide women with more flexibility in family planning and career development. Additionally, delaying menopause may contribute to improved overall health and longevity, as menopause is associated with increased risks of osteoporosis, cardiovascular disease, and cognitive decline. Barnes-Lentz's approach highlights the potential of personalized medicine and lifestyle interventions in managing aging processes. If successful, these experimental treatments could pave the way for new therapeutic options for women seeking to extend their reproductive lifespan and improve their quality of life.
What's Next?
Barnes-Lentz plans to continue her experimental protocols and aims to get pregnant later this year. She is also interested in exploring post-baby interventions, as there is limited data on the effects of these treatments on pregnant or postpartum women. The ongoing VIBRANT study on rapamycin's effects on ovarian aging may provide further insights and validation for her approach. As research progresses, there may be increased interest and investment in developing treatments that target ovarian aging, potentially leading to broader availability and acceptance of such interventions in the future.
